Producing solid-state formulations of biologics remains a daunting task despite the prevalent use of lyophilization and spray drying technologies in the biopharmaceutical industry.The challenges include protein stability (temperature stresses), high capital costs, particle design/controllability, shortened processing times and manufacturing considerations (scalability, yield improvements, aseptic operation, etc.).Thus, scientists/engineers are constantly working to improve existing methodologies and exploring novel dehydration/powder-forming technologies.Microglassification is a dehydration technol. that uses solvent extraction to rapidly dehydrate protein formulations at ambient temperatures, eliminating the temperature stress experienced by biologics in traditional lyophilization and spray drying methods.The process results in microparticles that are spherical, dense, and chem. stable.In this study, we compared the mol. stability of a monoclonal antibody formulation processed by lyophilization to the same formulation processed using Microglassification.Both powders were placed on stability for 3 mo at 40°C and 6 mo at 25°C.Both dehydration methods showed similar chem. stability, including percent monomer, charge variants, and antigen binding.These results show that Microglassification is viable for the production of stable solid-state monoclonal antibody formulations.